Rapamycin (Sirolimus) Licensed by Pfizer

Catalog No.S1039

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Price Stock Quantity  
USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rapamycin (Sirolimus) Chemical Structure

Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18

Validation & Quality Control

Cited by 62 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets mTOR [1]
(HEK293 cells)
IC50 ~0.1 nM
In vitro Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29M1\pWGN6fG:2b4jpZ{BCe3OjeR?=MW[xNEBvVQ>?NFXrOmk4OiCqMXrEUXNQMVHQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm=MkDZNlQ6ODB6N{O=
HT-29NECzVlFEgXSxdH;4bYMhSXO|YYm=MUmxNEBvVQ>?NEGydHc4OiCqM2S1TWROW09?MVPQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl?Ml7uNlQ6ODB6N{O=
HT-29Mnj1R5l1d3SxeHnjJGF{e2G7M3HFe|ExKG6PNWTIfXlQPzJiaB?=MVXEUXNQM4\3eHBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6NYDwO2dFOjR7MEC4O|M>
PC3MWHLbY5ie2ViQYPzZZk>Mn\YNVAxKG6PMX[xJIg>M2m2S2ROW09?NVva[o9vWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4>NHrt[|YzOTl5OE[4Ny=>
PC3M4LUTWtqdmG|ZTDBd5NigQ>?MYWxNFAhdk1?MlGzNUBpNFL5enJFVVORMWjEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?NXv6WllNOjF7N{i2PFM>
PC3MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYixMlUh|ryPMWixJIg>NG[0UVRFVVORNEDMWodKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2=MmL4NlE6Pzh4OEO=
HEK293NVH6XI1LTnWwY4Tpc44hSXO|YYm=NF3zZm0yODBibl2=M1zXT|ghcA>?MmTXSG1UVw>?MmixTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6PNVLVZXVQOjF3M{mzNFE>
BT-20NHnQeYtMcW6jc3WgRZN{[Xl?MlTmNlAh|ryPM4DW[WROW09?M{HtemRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:wNHT0SIMzOTN3M{W1NS=>
U937M4C2SmFvfGmkYXP0[ZJq[WxiQYPzZZk>NUDNXnNIPTBizszNNX;GdXdVPDhiaB?=NIDCe21FVVORM37ueGlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?=NXO3RYV5OjFzNEKxNFY>
U937M33LN2FvfGmkYXP0[ZJq[WxiQYPzZZk>M4iwTVUxKM7:TR?=NIqzOo41QCCqM2rITGROW09?M3K1UGRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN?NFfER5EzOTF2MkGwOi=>
U937M2LuNWFvfGmkYXP0[ZJq[WxiQYPzZZk>M4jneVUxKM7:TR?=NF\XO4Q1QCCqM2PXd2ROW09?M3vyd2Rw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{NXTTUWdWOjFzNEKxNFY>
MCF-7MlPDRZV1d3CqYXf5JGF{e2G7M3ryb|MxKG6PNXvCUGhQPCCqMUnEUXNQMlXZTY5lfWOnczDheZRweGijZ4m=M2HJT|IxODJ6MUO0
U87MGM171U2tqdmG|ZTDBd5NigQ>?NX;1SZh2OSEQvF2=MV:2JIg>M4PDSmROW09?NE\odpVRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?=M3XieVE6QDR6NEC0
U87MGNHuzTpZMcW6jc3WgRZN{[Xl?M2XHZ|Eh|ryPNEnZW2k3KGh?MnTCSG1UVw>?M320SHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;uMXexPVg1QDRyNB?=
U87MGNUjZSZVpU2mwYYPlJGF{e2G7NWfTfmRrOSEQvF2=NY\ER5hXPiCqNHPtPJZFVVORM1PCR2Rw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wNITm[|cyQTh2OESwOC=>
U87MGNF\TbZlMcW6jc3WgRZN{[Xl?M3LYRlEh|ryPMm[wOkBpMWPEUXNQMWrEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44>NWKzcFRWOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rhebM1zqc2F2fG:yaHHnfUBCe3OjeR?=NHzOcm0xNjJizszNNXrpR253OjRiaB?=M4DqWWROW09?MmHVTY5lfWOnczDheZRweGijZ4m=NV;LdHFkOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3M3mwd2F2fG:yaHHnfUBCe3OjeR?=NXjLNHhEOC5{IN88US=>MlzENlQhcA>?NWLwUpdQTE2VTx?=M2npVWlv\HWlZYOgZZV1d3CqYXf5NI\iU|YyQDN7MUm0PS=>
H4NXXO[4lSTnWwY4Tpc44hSXO|YYm=NGnSSWYxNjJizszNNGPISIMzPCCqM4jufmROW09?NGHHXYRKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{NEGxfY8yQDB{NEW4OC=>
HeLaMXXGeY5kfGmxbjDBd5NigQ>?Mn32NVAxKG6PM2\ESlM3KGh?NWHnb3JCTE2VTx?=NIrhNHJKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9vM2HFN|E4PTZ|M{i1
HeLaM4LFXmZ2dmO2aX;uJGF{e2G7MW[xNFAhdk1?NXvTXJhGOzZiaB?=NXnLVYNUTE2VTx?=M4jhXGlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?NHTTRoMyPzV4M{O4OS=>
HeLaM{XFOmZ2dmO2aX;uJGF{e2G7NI\2bXEyODBibl2=Mn32N|YhcA>?M2LtTWROW09?M4P4emlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=>Mni1NVc2PjN|OEW=
SYFMUHGeY5kfGmxbjDBd5NigQ>?NVPsPGlmOTByIH7NMUSyOEBpMoXRSG1UVw>?M1jiXGlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=>NWjDc|NbOTd3NkOzPFU>
SYFMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVWxNFAhdk1?NFT0fmwzPCCqNUXnd|Z2TE2VTx?=NH[3cW9KdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzzM17wclE4PTZ|M{i1
HEK293TNHjTe5RCdnSrdnnyZYwhSXO|YYm=M1TL[VEhdk1?NWXMNVlLPCCmNXjoRYd{TE2VTx?=MVfJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?=NVHNeZAzOTd2OEW1NFE>
HEK293TNWLTPGRJSW62aY\pdoFtKEG|c3H5NXLBZ3BuOSCwTR?=NGnrZlc1KGR?NXS0VXlPTE2VTx?=NFHP[4RKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=>MXmxO|Q5PTVyMR?=
PBMCMWrGeY5kfGmxbjDBd5NigQ>?NFe5Z3YyKG6PM3rBOFE1KGR?NG[4TYpFVVORNGXCUYdT\WS3Y3XzJGNEWjViZHXud4l1gQ>?NG[5ZoEyPzR6NUWwNS=>
PBMCMWjGeY5kfGmxbjDBd5NigQ>?NIjERmcyKG6PM3rNTlE1KGR?NV;jVVhJTE2VTx?=Mn3SSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk>M1XvV|E4PDh3NUCx
HEK293 cellsNIPaZnBMcW6jc3WgRZN{[Xl?NFzRTVM2OCCwTR?=M3HaU|Q2KG2rbh?=NIHCbIpFVVORNFrm[Y9KdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6PM{KxSlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-lucNFv4UYhHfW6ldHnvckBCe3OjeR?=NYLldGhGOTByIH7NM2G1bFQhcA>?NG\sZo5FVVORNVKz[opkUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN?NEXhbpQyPzF{OEK2Ni=>
Human mixed lymphocyteMk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnaVolpPSCwTR?=M4W2OWROW09?M2XiXmlEPTB;MT62JI5ONg>?MknlNVYyQDV6NkW=
Lewis rat lymph node cellsNXHvdmtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfsOUDPxE1?MU\EUXNQNXqyUYRGUUN3ME2yMlYh|ryPM4q0T|E3OTh3OE[1
cells from the thymus of normal BALB/c miceNVmwV5JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWOxNEBvVQ>?NGe0[Zo4OiCqMYfEUXNQNULMSHN[UW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=>M{HqfVExODJzOUS4
MRK-nu-1NHOxRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHSRVBKSzVyPUCuPFQ2KHCPNGHBXplUSU6JRWK=
OCUB-MMojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTVwMkSgdG0>M3nhfHNCVkeHUh?=
SF539NV7WUWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGC3ZnNKSzVyPUGxMlYheE1?M3jJVXNCVkeHUh?=
ES4MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH:xNohKSzVyPUKxMlUheE1?MUDTRW5ITVJ?
RL95-2MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rNXWlEPTB;MUC3JJBOMonjV2FPT0WU
LC-2-adMlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DCSWlEPTB;NEKzJJBOMVTTRW5ITVJ?
DaudiMkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWX5bYhyUUN3ME20N|QheE1?MX;TRW5ITVJ?
NTERA-S-cl-D1MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXjTWM2OD12NEOgdG0>MnHoV2FPT0WU
OS-RC-2NWOwTpdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLaTWM2OD14NUKgdG0>M1nhV3NCVkeHUh?=
VA-ES-BJNWn6VlhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\1c4lKSzVyPUeyN{BxVQ>?MlTCV2FPT0WU
GR-STNV65dVE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTh2NjDwUS=>NHzKWZNUSU6JRWK=
SW872MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfYcHJjUUN3ME24OFYheE1?MY\TRW5ITVJ?
NOS-1NH7le49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTh5MTDwUS=>MofvV2FPT0WU
MC116MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPoOoZKSzVyPUm4OUBxVQ>?NFmwXG1USU6JRWK=
NCI-H1355NU\sb5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEWze5RKSzVyPUGuNFEhdk1?NVrWPVIyW0GQR1XS
RPMI-8226MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LoemlEPTB;MT6xPUBvVQ>?NGf5SW5USU6JRWK=
TE-15MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPBTWM2OD1zLkO2JI5OMYXTRW5ITVJ?
Ramos-2G6-4C10MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfUW5ZKSzVyPUGuOFYhdk1?NITGNG9USU6JRWK=
KU812NYnmXIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEezSndKSzVyPUKuNFEhdk1?MUPTRW5ITVJ?
EW-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjHWpNKSzVyPUKuNVchdk1?MVTTRW5ITVJ?
KS-1M4OyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJwNEWgcm0>NIWye5NUSU6JRWK=
SK-LMS-1MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPKZWhKSzVyPUKuOFkhdk1?NVfy[HFJW0GQR1XS
TGBC1TKBM2[wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJwNkmgcm0>MX\TRW5ITVJ?
TE-6M3zWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXxTWM2OD1{Lke3JI5OMlfVV2FPT0WU
ETK-1MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnvVFh2UUN3ME2yMlgzKG6PNWS1SZMyW0GQR1XS
BE-13MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJwOUmgcm0>NUfWXGhGW0GQR1XS
A3-KAWMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XIOGlEPTB;Mj65PUBvVQ>?NY[0RXdCW0GQR1XS
TE-10MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzLbHNmUUN3ME2zMlMhdk1?MnzXV2FPT0WU
DOHH-2NHnTTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPyUox[UUN3ME2zMlM2KG6PMXTTRW5ITVJ?
ES6MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnHXoRuUUN3ME2zMlQ{KG6PNWrOPXgzW0GQR1XS
OPM-2NF3xN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTRwMUWgcm0>MlraV2FPT0WU
SH-4MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nIdmlEPTB;ND6zOEBvVQ>?NHXPV2FUSU6JRWK=
NB13M{nUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUSwdmF{UUN3ME20MlM3KG6PNXrYcYdHW0GQR1XS
HUTU-80NXjLSGZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrnTWM2OD12LkSyJI5OM3\EdXNCVkeHUh?=
CCRF-CEMMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHQTWM2OD12Lkm0JI5ONXn2Sm84W0GQR1XS
TGBC24TKBNHnx[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHpTWM2OD13LkWxJI5OM3PLdHNCVkeHUh?=
697NYPFU4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXH2V4pRUUN3ME22MlI5KG6PNXrLeIc2W0GQR1XS
J-RT3-T3-5MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF60UpBKSzVyPU[uOFYhdk1?NGTmU|FUSU6JRWK=
KALS-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWC3SJpkUUN3ME22MlU3KG6PM2HLenNCVkeHUh?=
no-10Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELTTVZKSzVyPUeuNlkhdk1?NEfJfG9USU6JRWK=
SK-NEP-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;HTWM2OD16Lke5JI5OM4TwUXNCVkeHUh?=
L-540NX\Bc483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonWTWM2OD1zMD60NkBvVQ>?NWPOXVE2W0GQR1XS
JiyoyeP-2003MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v5[WlEPTB;MUCuPVQhdk1?MlLtV2FPT0WU
HHM3nuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTFzLkO5JI5OM4fUNnNCVkeHUh?=
SRMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17oR2lEPTB;MUGuOFUhdk1?NIXudWtUSU6JRWK=
QIMR-WILMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTFzLki1JI5ONFjFem9USU6JRWK=
A4-FukMoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTF|LkGyJI5OMl3VV2FPT0WU
CESSM2XBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3mwV2lEPTB;MUOuNVMhdk1?NXG3U4N6W0GQR1XS
KE-37NEfuT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTF4LkC3JI5ONYn0eYQ4W0GQR1XS
SK-UT-1M2jIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\JOItKSzVyPUG2MlgyKG6PMXPTRW5ITVJ?
SIG-M5MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILnWpJKSzVyPUG3MlI2KG6PNUDoVZMxW0GQR1XS
HTMm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvQeXBKSzVyPUG3MlYhdk1?MUfTRW5ITVJ?
DELNIOzVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fBN2lEPTB;MUeuPVkhdk1?MVLTRW5ITVJ?
SK-PN-DWNICxRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvXdIJKSzVyPUKwMlI{KG6PMlG3V2FPT0WU
RPMI-8402MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvzeHRKSzVyPUKxMlc4KG6PMkLnV2FPT0WU
RPMI-6666NET3[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M322[2lEPTB;MkSuOFIhdk1?MYfTRW5ITVJ?
NCI-H720NETLcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTJ3LkSxJI5ONYC5dGl4W0GQR1XS
EW-16M4TTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jsSGlEPTB;Mk[uPFchdk1?M4rxOXNCVkeHUh?=
BL-70MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DVPWlEPTB;MkiuN|ghdk1?MWHTRW5ITVJ?
SF126MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrNZpA1UUN3ME2zNE4{QCCwTR?=NHTCNnJUSU6JRWK=
BC-1M33WNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTNzLkK2JI5OM4PDc3NCVkeHUh?=
MHH-PREB-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq3S21jUUN3ME2zNk41PCCwTR?=MkTUV2FPT0WU
A101DNIqw[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTN{Lk[yJI5OMl63V2FPT0WU
NMC-G1NEXlTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTN|Lk[3JI5OMn7aV2FPT0WU
LB1047-RCCM{XZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITCc3lKSzVyPUO0MlY6KG6PNYOxXZVKW0GQR1XS
EM-2MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYSz[HhRUUN3ME2zPE42OyCwTR?=MYjTRW5ITVJ?
COLO-684NHSxXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTN7Lkigcm0>MV;TRW5ITVJ?
BeckerMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3ITWM2OD12MT6wOUBvVQ>?MnPvV2FPT0WU
BL-41NVP4Z|BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTR|Lk[2JI5OM{jEcnNCVkeHUh?=
MDA-MB-134-VIMn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTR2LkCyJI5ONXPKNnMxW0GQR1XS
L-363NXXRTJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTzbJdFUUN3ME20OE44OyCwTR?=M2nS[HNCVkeHUh?=
ECC4NVTvfnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2j5[2lEPTB;NESuO|ghdk1?NHXOV5ZUSU6JRWK=
A388MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoCzTWM2OD12ND64NkBvVQ>?M{j5TnNCVkeHUh?=
HELNF6xNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17aPWlEPTB;NEmuO|khdk1?MojVV2FPT0WU
RKONYjvcHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\McWlEPTB;NUCuNlkhdk1?M4nsc3NCVkeHUh?=
KINGS-1M{m5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\sUWlEPTB;NUGuOVUhdk1?NYPrbmJoW0GQR1XS
EB-3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{C1TWlEPTB;NUKuOlchdk1?MmDmV2FPT0WU
ARH-77NVXhWmppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Hjb2lEPTB;NUKuPEBvVQ>?MXnTRW5ITVJ?
GCIYNV[xcmFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTTW|ZKSzVyPUWzMlQ3KG6PMl7xV2FPT0WU
NCI-H1304MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvjTWM2OD13Nz6yNkBvVQ>?MY\TRW5ITVJ?
KARPAS-299MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXLOY9tUUN3ME22NU45OiCwTR?=M1LGdnNCVkeHUh?=
IA-LMM4T2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTZ6LkGzJI5ONXG2PZBiW0GQR1XS
GI-1MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTdyLkO5JI5ONIPLeWlUSU6JRWK=
TE-11M3voRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Dwe2lEPTB;N{euNVchdk1?MXzTRW5ITVJ?
LS-411NMo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\BTWM2OD15Nz61O{BvVQ>?NFrLfo1USU6JRWK=
no-11NIXQdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTh|LkK0JI5OMoX5V2FPT0WU
MV-4-11NH3iNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[0TWM2OD16Mz63N{BvVQ>?MYTTRW5ITVJ?
BV-173MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTh|Lkm3JI5OMWHTRW5ITVJ?
CMKNFXjXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonsTWM2OD16ND6xOkBvVQ>?NWjEc|hGW0GQR1XS
LC4-1NI\0epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPETWM2OD16Nj63NkBvVQ>?MnOzV2FPT0WU
COR-L279MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTh5LkK1JI5ONITIeIFUSU6JRWK=
NCI-H209NXHUToJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTh5LkSxJI5OMY\TRW5ITVJ?
RajiMkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\2UmlEPTB;OEmuO|Ihdk1?NX\6S|RNW0GQR1XS
LB996-RCCNF76e2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILKPFZKSzVyPUmzMlQ{KG6PMlvEV2FPT0WU
NCI-H526NFvzPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHrTWM2OD17Mz61PUBvVQ>?MUHTRW5ITVJ?
KGNMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rCdmlEPTB;OU[uNlkhdk1?MlP6V2FPT0WU
MOLT-4MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTl4Lke5JI5OMUTTRW5ITVJ?
PF-382NW[3W4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\zO2lEPTB;OU[uO|khdk1?M{focXNCVkeHUh?=
BC-3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPETWM2OD17OT6xPEBvVQ>?M33kd3NCVkeHUh?=
KARPAS-422MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7LV2oyUUN3ME2xNFIvODlibl2=M{n1fXNCVkeHUh?=
SBC-1NVTKW4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrsNWduUUN3ME2xNFcvPzVibl2=MojwV2FPT0WU
LC-1FMnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHaTWM2OD1zMEiuNFUhdk1?NXjkO256W0GQR1XS
GB-1NEXlRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjxe294UUN3ME2xNFkvODJibl2=NUDvVnZpW0GQR1XS
SNB75NHe3e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{S1ZWlEPTB;MUG5MlY6KG6PM2P0[HNCVkeHUh?=
BB65-RCCNYS4cFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWq4OnZvUUN3ME2xNVkvQTNibl2=NFHEdJpUSU6JRWK=
NCI-N87MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4H2OGlEPTB;MUKxMlk5KG6PNFjFd2NUSU6JRWK=
IST-MEL1NE\CWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDNTWM2OD1zMkKuN|ghdk1?MV\TRW5ITVJ?
HOP-62NVT4Rm53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rOPWlEPTB;MUK2Mlg6KG6PMXvTRW5ITVJ?
ACNNVH0PXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPnXGNxUUN3ME2xOFYvPzVibl2=M1nRXXNCVkeHUh?=
DMS-114NXvneWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljBTWM2OD1zNUCuOlchdk1?MXPTRW5ITVJ?
MLMAMm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTF3OT64PEBvVQ>?MVrTRW5ITVJ?
HT-144NISyN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rYXmlEPTB;MU[1MlQ{KG6PMmm4V2FPT0WU
C2BBe1NV[xZVZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPiUYpKSzVyPUG2O{44PiCwTR?=MnuzV2FPT0WU
L-428MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1T0[mlEPTB;MUe3Mlchdk1?NEfpbJhUSU6JRWK=
DU-4475NYjyUGlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTF6Nz62PEBvVQ>?NXTTbZY4W0GQR1XS
CP67-MELNFjCZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPBfWJKSzVyPUG5PU4{QCCwTR?=MUPTRW5ITVJ?
MEG-01M4\QOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfic2ZKSzVyPUKwNU46PiCwTR?=MkP4V2FPT0WU
IST-SL2NXq5XHFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnsTWM2OD1{MEiuOlMhdk1?MoThV2FPT0WU
ES8MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLZTWM2OD1{MkWuPVQhdk1?NIq0T5JUSU6JRWK=
COLO-800NH21O|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnztTWM2OD1{M{WuNlghdk1?M3PZU3NCVkeHUh?=
MFH-inoM37ibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjPR4RKSzVyPUKzOU45PCCwTR?=M3fKdnNCVkeHUh?=
OVCAR-4M4Pyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPrPXJKSzVyPUKzO{4zPCCwTR?=M37UfnNCVkeHUh?=
PSN1NETEbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJ2Mj63NUBvVQ>?M1LS[nNCVkeHUh?=
EW-12M1e4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTKS|dKSzVyPUK0N{4yKG6PNHXQc5ZUSU6JRWK=
HCC1599NV7SOFNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzaTWM2OD1{NkGuOFchdk1?M1X2WnNCVkeHUh?=
SJSA-1M4fJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;w[WJ2UUN3ME2yO|EvPDZibl2=MVLTRW5ITVJ?
ST486MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTJ7Nj6xOEBvVQ>?MYTTRW5ITVJ?
NOMO-1M2\0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnUUZhKSzVyPUOwNE4zOSCwTR?=NUfOcHB1W0GQR1XS
MN-60MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLZ[nAzUUN3ME2zNFUvOzJibl2=M1TWe3NCVkeHUh?=
HCC1187NUPDcY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LNO2lEPTB;M{C3MlI2KG6PNHvvc4lUSU6JRWK=
SW982NXXUXHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1v5SWlEPTB;M{G0Mlc2KG6PNGT0NHVUSU6JRWK=
LB647-SCLCMlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTN{OD63NUBvVQ>?NVjhWVNGW0GQR1XS
HC-1MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTN|NT61JI5OMontV2FPT0WU
EHEBNYPQO2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\BfnFbUUN3ME2zN|cvPTJibl2=M37sd3NCVkeHUh?=
TURNWPQVWZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljNTWM2OD1|NkOuPVUhdk1?M2O1VHNCVkeHUh?=
LU-139Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2q3c2lEPTB;M{e4MlAzKG6PM1XmRXNCVkeHUh?=
NB1NVfJWW92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrFRWh2UUN3ME2zPFQvPDVibl2=Mo\BV2FPT0WU
BB30-HNCNHrVNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTN6OD6zNkBvVQ>?NUfQeo4{W0GQR1XS
HAL-01NYPibmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfLTWM2OD1|OEmuNlYhdk1?NGLCSlNUSU6JRWK=
K5NEn0PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTWTWM2OD12MUGuN|chdk1?MXTTRW5ITVJ?
MZ2-MELM2CyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzhXmVKSzVyPUSxN{43PCCwTR?=NWHmNI9mW0GQR1XS
RXF393M1;GOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjrV3dKSzVyPUSxOk41PSCwTR?=M2Lu[XNCVkeHUh?=
NCI-H1648NWnNR|VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTRzNz61N{BvVQ>?NVT3SYY2W0GQR1XS
TE-12MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHzTWM2OD12M{SuNlYhdk1?MVLTRW5ITVJ?
EoL-1-M{DUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTR|Nz65PEBvVQ>?NVm4V4xGW0GQR1XS
JARNILaSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo[xTWM2OD12M{iuOlIhdk1?NH\JXVFUSU6JRWK=
DSH1Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLUTWM2OD12NUiuPVEhdk1?MXHTRW5ITVJ?
NCI-H187NFW2OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXwTWM2OD12NkKuPFEhdk1?NUGzfnA5W0GQR1XS
HCE-4M3nGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTR5Nz62OkBvVQ>?MWTTRW5ITVJ?
8-MG-BAMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zjS2lEPTB;NUixMlUzKG6PMUfTRW5ITVJ?
KLEMnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLsTWM2OD13OEWuNkBvVQ>?MkXnV2FPT0WU
KNS-42MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTV6Nj64NUBvVQ>?MkLzV2FPT0WU
MSTO-211HNGLY[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTU[mNlUUN3ME22NFkvPzRibl2=M1L3PXNCVkeHUh?=
GDM-1Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTZzND6wPUBvVQ>?MliwV2FPT0WU
TE-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPoRZVKSzVyPU[0Ok4yOiCwTR?=NX3mWVVUW0GQR1XS
BT-474MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\sV2NOUUN3ME22OFcvODZibl2=NEjScllUSU6JRWK=
KARPAS-45MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;vVWlEPTB;NkS3MlYhdk1?MmrPV2FPT0WU
MOLT-16NUDScVdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPZTWM2OD14NEeuPVMhdk1?NX64PGtWW0GQR1XS
KURAMOCHINYnKTZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDJTWM2OD14NUeuOVEhdk1?MXHTRW5ITVJ?
K-562MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rzT2lEPTB;Nk[5MlUyKG6PM1LYPXNCVkeHUh?=
EKVXNGTCVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfoTWM2OD14N{KuO|Ehdk1?MVTTRW5ITVJ?
GAKM{Pzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjaU5RRUUN3ME22O|UvOyCwTR?=NUHHfW9LW0GQR1XS
NCI-SNU-5NXLxeY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTZ7MD6wNUBvVQ>?M1TEUHNCVkeHUh?=
NCI-H2126MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEf6O2xKSzVyPUeyOk45PyCwTR?=MVXTRW5ITVJ?
CTV-1NEKxZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDrXVl6UUN3ME23OFQvQSCwTR?=MWHTRW5ITVJ?
SW962MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DIZmlEPTB;N{S4MlQ1KG6PM1P1UHNCVkeHUh?=
MONO-MAC-6Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTJTWM2OD15NU[uPVMhdk1?MnPPV2FPT0WU
NCI-H748M2TP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvyNoJCUUN3ME23OVgvQTlibl2=NH2yS|hUSU6JRWK=
NCI-H524MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TZSGlEPTB;N{iwMlc{KG6PM2LZN3NCVkeHUh?=
LS-123MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFv1WZBKSzVyPUe5OU43QSCwTR?=MkHRV2FPT0WU
NB7NIPBZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2m1UmlEPTB;OEG0MlE1KG6PM4XyWXNCVkeHUh?=
LS-1034M4rvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2L1bmlEPTB;OEK4Mlk5KG6PM17OR3NCVkeHUh?=
TE-5M1z0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTh6Mz61OkBvVQ>?NYXtVYZXW0GQR1XS
A704NIW1SI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXyTWM2OD16OUmuNVUhdk1?MojSV2FPT0WU
TK10M{n5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPoVVRKSzVyPUmxOk4xOyCwTR?=NYnWWoI3W0GQR1XS
NCI-H345NX36WJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13ETmlEPTB;OUSzMlIzKG6PMoHYV2FPT0WU
CGTH-W-1NUfF[nI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnWyTWM2OD17NEiuNVMhdk1?MV\TRW5ITVJ?
NCI-H510AM4jTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHObYZKSzVyPUm4OU4yOiCwTR?=M3T5PXNCVkeHUh?=
NCI-H1963NYHYUHdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7ZVVBTUUN3ME2xMlA{Ojl{IN88US=>MXXTRW5ITVJ?
SCC-3MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nGdGlEPTB;MT6wN|QyPCEQvF2=Mn;VV2FPT0WU
EW-11NVjIVpZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{j3RWlEPTB;MT6wPFc1OyEQvF2=MWXTRW5ITVJ?
CPC-NMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7lfY1KSzVyPUGuNFg5KM7:TR?=NG\vWZdUSU6JRWK=
NCI-H1417M4HFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7GN4FVUUN3ME2xMlEzOjZizszNM1i5ZXNCVkeHUh?=
DG-75NXTvNGVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfpO2ROUUN3ME2xMlE3Ojh3IN88US=>M1nIUnNCVkeHUh?=
HD-MY-ZNEHS[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f0[mlEPTB;MT6xOlQyPiEQvF2=NHrXXVZUSU6JRWK=
ATN-1NFmzSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFwMk[yNFkh|ryPMkS2V2FPT0WU
KM-H2NVz4PGxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{ezU2lEPTB;MT6yOlQxQCEQvF2=MlSwV2FPT0WU
NCI-H2081MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITnfJBKSzVyPUGuNlY3OzdizszNMV\TRW5ITVJ?
HL-60NXW2d3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHP2blZKSzVyPUGuNlY6PTlizszNMn7TV2FPT0WU
DBMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDHTWM2OD1zLkK3NlQzKM7:TR?=MoPsV2FPT0WU
NCI-H1522M2nEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTFwMki4PFch|ryPMXrTRW5ITVJ?
AM-38NEDwbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwM{C3NkDPxE1?MoLEV2FPT0WU
NCI-H446NUDPUmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7aTWM2OD1zLkOyNVIyKM7:TR?=MmH2V2FPT0WU
SU-DHL-1NHXDbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfmTWM2OD1zLkOyPFAyKM7:TR?=MlXyV2FPT0WU
NH-12NX\2ZWFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoCxTWM2OD1zLkO2N|c1KM7:TR?=MmDBV2FPT0WU
DMS-79MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\jTWM2OD1zLkO2PFY3KM7:TR?=NWLqWXFQW0GQR1XS
NCI-H716M4LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFwM{i5PFYh|ryPNFLhXG5USU6JRWK=
ML-2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFwNEG1Nlkh|ryPNUnkXW1rW0GQR1XS
NB10NILHPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPpTWM2OD1zLkS2OlMzKM7:TR?=NH\DcY5USU6JRWK=
ONS-76M{jxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnJXHNKSzVyPUGuOVM2PjlizszNMlHKV2FPT0WU
LOUCYNInsem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInoRmNKSzVyPUGuOVQ3PTdizszNMVzTRW5ITVJ?
SCLC-21HMnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDkOWRUUUN3ME2xMlU5PTh{IN88US=>NYrQcHJiW0GQR1XS
TGWMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTFwNkO5O|Uh|ryPNWHWeHoxW0GQR1XS
LXF-289NXL5TGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXTTWM2OD1zLkezNlY5KM7:TR?=MVLTRW5ITVJ?
BB49-HNCMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwN{O1PFYh|ryPNXXCUlBSW0GQR1XS
NCI-H747M1HvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTFwN{WzOFYh|ryPMnnQV2FPT0WU
LU-165NIHPZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1joV2lEPTB;MT64OFk5PiEQvF2=MoHnV2FPT0WU
OMC-1M3vYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fNfmlEPTB;MT65OVA3PiEQvF2=MoG0V2FPT0WU
RCC10RGBM37sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjTTWM2OD1zLkm1PFE4KM7:TR?=M{jNW3NCVkeHUh?=
SW684NGLoRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7mTWM2OD1zLkm2NFk6KM7:TR?=MVPTRW5ITVJ?
TE-8M1HMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfETWM2OD1{LkC1OVU6KM7:TR?=M4mxc3NCVkeHUh?=
SK-N-DZMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\KTWM2OD1{LkGzNlc1KM7:TR?=MnywV2FPT0WU
EVSA-TNVHNVZh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvQOmtKSzVyPUKuNVc{OTVizszNNILXbmZUSU6JRWK=
KASUMI-1MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJwMUi4NVUh|ryPMl3jV2FPT0WU
NKM-1MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{e2cWlEPTB;Mj6yOVQ4OiEQvF2=NVi1T21OW0GQR1XS
CAL-148NWrHb|Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1u5O2lEPTB;Mj6zN|YyPCEQvF2=MlH1V2FPT0WU
NCI-H64MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzxTpRrUUN3ME2yMlM1OjN{IN88US=>NYDFUmlsW0GQR1XS
KNS-81-FDNYWzZ|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXjXYVJUUN3ME2yMlM3PjJizszNNGGzSYZUSU6JRWK=
KM12M2Pkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDYWpY{UUN3ME2yMlQxQDN7IN88US=>MXfTRW5ITVJ?
SW954MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPvTWM2OD1{LkS3O|c6KM7:TR?=M3HWbXNCVkeHUh?=
NCI-H1395NV3Ve2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnkenQ4UUN3ME2yMlUzPjR3IN88US=>MVfTRW5ITVJ?
DJM-1NFy3d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLCe3dDUUN3ME2yMlYxPjNizszNNHOwR5JUSU6JRWK=
COLO-668NYfxSlRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PrOWlEPTB;Mj64NlY6PSEQvF2=MmSyV2FPT0WU
NCI-H1436NV\0dVl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTvNmh4UUN3ME2yMlg2PjF3IN88US=>MkKxV2FPT0WU
LB2241-RCCMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTJwOE[4N|kh|ryPMYLTRW5ITVJ?
GT3TKBNH7QZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXFTWM2OD1{Lki5NFU2KM7:TR?=NXXodnlkW0GQR1XS
COLO-824NGPrRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XSUWlEPTB;Mj64PVc3QCEQvF2=Mlv3V2FPT0WU
ES1MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnETWM2OD1{Lki5PFc6KM7:TR?=Mnj4V2FPT0WU
LB771-HNCMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDXcmxKSzVyPUKuPVA6PDZizszNNGHXe5lUSU6JRWK=
GI-ME-NM{Xacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\FTWsxUUN3ME2zMlAxQTB2IN88US=>NH7td5JUSU6JRWK=
NALM-6MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXZUlNKSzVyPUOuNFA6OzNizszNMn\EV2FPT0WU
LU-134-AMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\yNWJKSzVyPUOuNFU1OjVizszNM3jHbXNCVkeHUh?=
DMS-153MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TONWlEPTB;Mz6wOVgzPCEQvF2=NFTaTVlUSU6JRWK=
MZ1-PCMoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Tt[2lEPTB;Mz6wPVA4QCEQvF2=NWXzRW5[W0GQR1XS
NCI-H1155NXXWXJZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTNwMUG2NUDPxE1?NF63[GJUSU6JRWK=
CAS-1M1fhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjKWItKSzVyPUOuNVM4ODdizszNNETjVGxUSU6JRWK=
D-502MGMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;YTWM2OD1|LkG0N|kh|ryPMULTRW5ITVJ?
NCI-H2141NIXGd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTNwMUe0OVIh|ryPMn2zV2FPT0WU
NB6M2n6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPwWopKSzVyPUOuNVgzPTlizszNMV;TRW5ITVJ?
NCCITMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\MTWM2OD1|LkKxPFA6KM7:TR?=NWDSTldxW0GQR1XS
NB69MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2D6TmlEPTB;Mz6zNVg6OSEQvF2=M13veHNCVkeHUh?=
JVM-2NGOwd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTNwM{[0N|Mh|ryPNYXqUnZSW0GQR1XS
K052M1;jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DqVWlEPTB;Mz6zO|k3QCEQvF2=M4jqbHNCVkeHUh?=
HCC2157M2qwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTNwNUOyNlgh|ryPNHfvTodUSU6JRWK=
KMOE-2NHz4SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\1ZWdHUUN3ME2zMlU1OjR{IN88US=>MnvKV2FPT0WU
SF268M2TJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfDT25KSzVyPUOuO|E2PTRizszNMl7NV2FPT0WU
CHP-126M4LnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLHb3E4UUN3ME2zMlc3PDV6IN88US=>MlLmV2FPT0WU
CP66-MELM3fyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTNwN{mwPVQh|ryPMYPTRW5ITVJ?
NCI-H69Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3teXlKSzVyPUSuNFE6OzZizszNNIfEOGdUSU6JRWK=
A253NIj0eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVr5dZdbUUN3ME20MlAzOTBzIN88US=>NFXhU2tUSU6JRWK=
NB14MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTRwMUC0O|kh|ryPNVzOUJNYW0GQR1XS
NCI-H1694NWq2dHNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHuTWM2OD12LkGzNVEzKM7:TR?=MXvTRW5ITVJ?
NCI-H2196NGfWfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4npc2lEPTB;ND6xO|E3QSEQvF2=MnPLV2FPT0WU
TE-9NVL5V2RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjtXHFKSzVyPUSuNVc2QDJizszNNUm4cJd5W0GQR1XS
D-283MEDMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[wZoFKSzVyPUSuNVg5PCEQvF2=NYfzUG9lW0GQR1XS
OCI-AML2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnCRlNVUUN3ME20MlE6PDh7IN88US=>MomwV2FPT0WU
D-263MGNULmZ3BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnz5TWM2OD12LkKyPVYyKM7:TR?=M2nVNHNCVkeHUh?=
MPP-89NX7WUHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTRwMkezNFQh|ryPNUDLR3hIW0GQR1XS
LAMA-84NES0OYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVj3d2FqUUN3ME20MlMxPDJzIN88US=>MkjGV2FPT0WU
LB373-MEL-DNWGx[25[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFr3fnFKSzVyPUSuN|Y4QDlizszNMknsV2FPT0WU
UACC-257MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnremZKSzVyPUSuN|k2OzRizszNM3nuZXNCVkeHUh?=
MC-CARNHv5[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7MV4NjUUN3ME20MlQ{QTlizszNM4f2[XNCVkeHUh?=
COLO-320-HSRMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PBNWlEPTB;ND60OFQzPyEQvF2=MlXlV2FPT0WU
P30-OHKM3W5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTRwNk[1PFEh|ryPMWLTRW5ITVJ?
UACC-812MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rhUGlEPTB;ND62PVE3OSEQvF2=NYnl[mVYW0GQR1XS
CTB-1NFXCUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnoTWM2OD12LkexOVU2KM7:TR?=Mn;WV2FPT0WU
ALL-POM3;OcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjjbndKSzVyPUSuPFQxPzdizszNMl;IV2FPT0WU
SK-MEL-2M{D5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfvTWM2OD12Lki2PVU2KM7:TR?=NWTGVHZsW0GQR1XS
TC-YIKM3m3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHFTWM2OD12Lkm3PVQzKM7:TR?=MljyV2FPT0WU
NCI-H1882M3zBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljETWM2OD13LkCyNFAyKM7:TR?=MkTVV2FPT0WU
MHH-CALL-2NFPBTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\DOmRKSzVyPUWuNFUxPDJizszNM2TTOXNCVkeHUh?=
U-87-MGM1\ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXsTWM2OD13LkC5OFY3KM7:TR?=MmPhV2FPT0WU
NCI-H1092Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTVwMk[1OVUh|ryPM1:wfHNCVkeHUh?=
TE-441-TM4\NXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHsfHB1UUN3ME21MlI4QDJizszNNVfNWWh2W0GQR1XS
SK-MEL-1NGX2bWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTFWo5KUUN3ME21MlI6ODR2IN88US=>NYroZ2hQW0GQR1XS
EW-22MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrPS4FvUUN3ME21MlI6PDZ4IN88US=>M1XwWXNCVkeHUh?=
MZ7-melMnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPKdWFSUUN3ME21MlQxPjlzIN88US=>MoHYV2FPT0WU
LP-1NYf4ZYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHGbI9bUUN3ME21MlQyOjlzIN88US=>MnPWV2FPT0WU
NCI-SNU-16M1H3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DRXGlEPTB;NT62OFA4PCEQvF2=MXPTRW5ITVJ?
LU-65NEP5OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzXOIlKSzVyPUWuO|Y{PzNizszNNFy4T2xUSU6JRWK=
CW-2NWnYPJRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLLTWM2OD13Lki1PVU6KM7:TR?=NETqN5VUSU6JRWK=
WSU-NHLNUXJWGdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHnRoJKSzVyPUWuPVUyPzRizszNM3LQSHNCVkeHUh?=
IST-MES1MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTVwOUW0OFMh|ryPMYTTRW5ITVJ?
U-266MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTJTWM2OD13Lkm4NlAzKM7:TR?=NGS1N4FUSU6JRWK=
TALL-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG3eHFKSzVyPU[uNVQ3QDhizszNNFT1ephUSU6JRWK=
Calu-6NHTlT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUi0PXZKUUN3ME22MlE2OzF4IN88US=>MYTTRW5ITVJ?
MMAC-SFNEPWfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3v3RWlEPTB;Nj6xPFU2PiEQvF2=NUXVWIlsW0GQR1XS
NCI-H82MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HqdGlEPTB;Nj6yNFQ5QSEQvF2=NF\vTnJUSU6JRWK=
RS4-11NGLCOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7xOYFqUUN3ME22MlI2QDl5IN88US=>M1fJcXNCVkeHUh?=
SNU-C2BM3HwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFL1SZRKSzVyPU[uOFA6PjlizszNNWW0W2NHW0GQR1XS
BOKUNUjDUFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH[xfWhKSzVyPU[uOFc2QTdizszNMmP6V2FPT0WU
C8166MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTZwNUW5NVIh|ryPM3fRdXNCVkeHUh?=
D-247MGNH;5W4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV31UVM6UUN3ME23MlA1OzR5IN88US=>MUPTRW5ITVJ?
EW-18NXHlS3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTdwMEeyPVIh|ryPMnn5V2FPT0WU
KG-1NVTlV21sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFmycZZKSzVyPUeuOlI4OzhizszNMnHGV2FPT0WU
REHNIfkZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTdwNkixNFkh|ryPMmLtV2FPT0WU
U-698-MNInIZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7rOXJGUUN3ME23Mlg1OzF3IN88US=>M125SnNCVkeHUh?=
KP-N-RT-BM-1NGX5W3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf6W5BKSzVyPUeuPVMxOjlizszNM37I[nNCVkeHUh?=
MS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Kz[WlEPTB;Nz65OlA1OSEQvF2=MoHhV2FPT0WU
SNU-C1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3yycGlEPTB;Nz65PFE6OiEQvF2=Mor4V2FPT0WU
SK-MM-2MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoO2TWM2OD16LkK2NFY2KM7:TR?=NH7Qc3JUSU6JRWK=
LAN-6M3SyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTxTWM2OD16LkOwNFAyKM7:TR?=MnzuV2FPT0WU
NEC8M1z1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRThwM{C2PVEh|ryPMl7JV2FPT0WU
NCI-H1770MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPY[YFUUUN3ME24MlM5ODB{IN88US=>MXjTRW5ITVJ?
D-336MGMoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRThwNECxNVYh|ryPMYLTRW5ITVJ?
COLO-829NWDkUmFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHi3[FhKSzVyPUiuOFg5PzlizszNNHGwSGRUSU6JRWK=
LS-513Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPYN49KSzVyPUiuOVk2QTlizszNNFfIdI5USU6JRWK=
YTMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDBeoNKSzVyPUiuOlI1OjdizszNNVPBd2xzW0GQR1XS
EW-24NFrmXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHuTJBlUUN3ME24Mlc3PTRizszNMXvTRW5ITVJ?
IST-SL1NFXRW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjPOHk4UUN3ME24Mlg3PTR|IN88US=>M4XtcHNCVkeHUh?=
CA46NGG2[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TW[mlEPTB;OD65OVA6QCEQvF2=NH[5NlRUSU6JRWK=
NCI-H1838NFLzellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXXXm5KSzVyPUiuPVg3ODJizszNNGHUUWJUSU6JRWK=
NCI-H719NYTiXFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmflTWM2OD17LkK1Nlc6KM7:TR?=M2TNbnNCVkeHUh?=
HCE-TMlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjiNYw1UUN3ME25MlMxQDVzIN88US=>NIfKcYxUSU6JRWK=
A498M2XLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjsTWM2OD17LkO2NVI1KM7:TR?=M4nXcnNCVkeHUh?=
LB831-BLCM{HOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\5TWM2OD17Lke2OVIyKM7:TR?=MoXSV2FPT0WU
SKM-1M4S1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjNV2hKSzVyPUmuPFU6PjNizszNNW[2dGtLW0GQR1XS
THP-1NWrZPXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTlwOU[5NVgh|ryPM{\rVnNCVkeHUh?=
SHP-77M{Ljc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfwTWM2OD1zMD60NFch|ryPNUjFdZFYW0GQR1XS
EW-3NHfGU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTFyLk[yPFkh|ryPMl\DV2FPT0WU
KY821NF;rNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo[wTWM2OD1zMD63OlMh|ryPMXzTRW5ITVJ?
NCI-SNU-1NEfOb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTFzLkCyNVch|ryPM3Gy[nNCVkeHUh?=
HCC2218Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3KzfmlEPTB;MUGuN|k5PiEQvF2=NHf2WZNUSU6JRWK=
IM-9NXviPGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fqTmlEPTB;MUGuOVExPiEQvF2=M2LQXXNCVkeHUh?=
NCI-H889NFXEeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFzLkWzNVMh|ryPMUPTRW5ITVJ?
HDLM-2NVrLNlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjaeIJWUUN3ME2xNk41OTV7IN88US=>M1nVcXNCVkeHUh?=
LB2518-MELNXHZNFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fSbWlEPTB;MUKuOlgyPSEQvF2=MYfTRW5ITVJ?
NCI-H23MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTF|LkK0NlUh|ryPM3XJUXNCVkeHUh?=
NB17NXTM[m1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWe2TnJpUUN3ME2xN{41PTd7IN88US=>NWDadohDW0GQR1XS
NCI-H322MNHvxSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u4RmlEPTB;MUSuOFA3QCEQvF2=MVXTRW5ITVJ?
SUP-T1MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF2LkSxN{DPxE1?Ml\GV2FPT0WU
ES3M13jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TtSGlEPTB;MUWuNFcxOyEQvF2=MljlV2FPT0WU
ES5MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjYTWM2OD1zNT6wO|g4KM7:TR?=NU[1dnNLW0GQR1XS
NCI-H1650NYHjbYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLlPYZKSzVyPUG1MlQ6PzlizszNMWPTRW5ITVJ?
NCI-H226MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnpd5pKSzVyPUG1Mlg4PjhizszNNXHOeGxxW0GQR1XS
COR-L88Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUP1RZJQUUN3ME2xOk4{OTRizszNNV7PNVhMW0GQR1XS
SCC-15MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnG4TWM2OD1zNj6zPFY6KM7:TR?=NX3MRZpTW0GQR1XS
GOTOM2PNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkS1TWM2OD1zNj60O|k{KM7:TR?=MXLTRW5ITVJ?
SIMANGnmTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrITWM2OD1zNj60PFAzKM7:TR?=MWrTRW5ITVJ?
NCI-H1299MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXlTWM2OD1zNz6xOVkyKM7:TR?=Ml\YV2FPT0WU
NCI-H1581MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7xbJRnUUN3ME2xO{41OjF7IN88US=>Mn\pV2FPT0WU
MHH-NB-11NWLXfZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPWTWM2OD1zNz65Olg{KM7:TR?=MUXTRW5ITVJ?
MFM-223NEHXR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3OyT2lEPTB;MUiuNFU{QCEQvF2=M1XaU3NCVkeHUh?=
ES7NUG5cmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTF6LkW0N|Eh|ryPMljxV2FPT0WU
JVM-3NHnhZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TXWGlEPTB;MUiuO|E4KM7:TR?=M1v1bXNCVkeHUh?=
RLMmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrpTGRKSzVyPUKwMlM5QCEQvF2=NGDVXHBUSU6JRWK=
EC-GI-10Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTJzLkKwOFEh|ryPM4XnW3NCVkeHUh?=
LNCaP-Clone-FGCNIrZdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml35TWM2OD1{MT62O|Y5KM7:TR?=NXPEV4pyW0GQR1XS
IMR-5NY\BR|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XWUGlEPTB;MkGuPFQ6PCEQvF2=NELWcVVUSU6JRWK=
KP-N-YSMnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rGR2lEPTB;MkGuPFc2KM7:TR?=MV;TRW5ITVJ?
Mo-TNEXySXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17FeWlEPTB;MkKuNlE5PSEQvF2=MXTTRW5ITVJ?
NCI-H128NYXzOWVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjsfGdJUUN3ME2yN{42QDV|IN88US=>Ml;yV2FPT0WU
RH-1NH\OWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHLTWM2OD1{Mz63PFY3KM7:TR?=MkiyV2FPT0WU
NCI-H2171NUHKbHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jwT2lEPTB;MkSuNlQ5PSEQvF2=NYPkNJQ{W0GQR1XS
RPMI-8866NW[wRm02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLaXnFKSzVyPUK2Mlc1OiEQvF2=MlmxV2FPT0WU
SK-N-FIMkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPvVHpKSzVyPUK3MlM5OTFizszNNHrZZnlUSU6JRWK=
LOXIMVIMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoC3TWM2OD1{Nz64NFUyKM7:TR?=NInobWlUSU6JRWK=
P31-FUJNGD0eJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTNzLkWzO|Qh|ryPMXnTRW5ITVJ?
KMS-12-PENX7uTZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvEflZKSzVyPUS5MlU{ODJizszNM2P6ZnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

Cell Assay:

[3]

Cell lines U87-MG, T98G, and U373-MG
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

Animal Study:

[7]

Animal Models Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
Formulation Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
Dosages ~4 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.

[2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02793544 Not yet recruiting Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblasti  ...more Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL) Center for International Blood and Marrow Transplant Rese  ...more Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Resource for Clinical Investigation in Blood and Marrow Transplantation August 2016 Phase 2
NCT02587325 Not yet recruiting Pulmonary Hypertension Aadi, LLC August 2016 Phase 1
NCT02806947 Not yet recruiting Acute GVHD Medical College of Wisconsin|National Heart, Lung, and Bl  ...more Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program July 2016 Phase 2
NCT02833506 Not yet recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ova  ...more Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (  ...more Roswell Park Cancer Institute|National Cancer Institute (NCI) July 2016 Phase 1

view more

Chemical Information

Download Rapamycin (Sirolimus) SDF
Molecular Weight (MW) 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms AY 22989,NSC-2260804
Solubility (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us